- Percutaneous cervical cordotomy (PCC) significantly reduces cancer pain and opioid consumption and improved QoL, with few adverse events (AEs), according to a preliminary analysis of a UK PCC patient registry.
- Median survival after PCC was only 1.3 months, suggesting patients were referred for PCC during the later stages of disease.
Why this matters
- Although cordotomy is usually prescribed for unilateral cancer pain in patients with
- Analysis of 159 patients (age ≥18 years) with cancer who underwent PCC for pain treatment performed during 2012-2017.
- Outcomes: relief of cancer pain.
- Funding: NCRI SuPaC Lung Cancer; North Wales Awyr Las fund; others.
- The median time from cancer diagnosis to PCC assessment was 13.3 (interquartile range, 6.2-23.2) months.
- PCC was linked to significantly reduced cancer pain and opioid dose (P<.001 for both>
- QoL improved significantly (P=.018) after PCC.
- Median survival period after PCC was 1.3 (interquartile range, 0.6-2.8) months.
- 4% of patients had PCC-related AEs.
- A small number of patients.
- Observational study.
- Limited pain characterization.
Coauthored with Vijay Rathod, PhD